Cost-Effectiveness of Saxagliptin in Type 2 Diabetes in the United States

被引：0
作者：
Bergenheim, Klas
Williams, Setareh A.
Bergeson, Joette G.
Stern, Lee
Sriprasert, Michelle
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2369-PO
引用
收藏
页码：A629 / A630
页数：2
相关论文
共 50 条
[31]   Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia [J].
Bekele, Mengistu ;
Norheim, Ole Frithjof ;
Hailu, Alemayehu .
MDM POLICY & PRACTICE, 2021, 6 (01)
[32]   Cost-Effectiveness Analysis of Empagliflozin as a Second-Line Therapy in Treatment Sequences of Patients With Type 2 Diabetes in The United States [J].
Reifsnider, Odette ;
Kansal, Anuraag ;
Pimple, Pratik ;
Aponte-Ribero, Valerie ;
Brand, Sarah ;
Shetty, Sharash .
CIRCULATION, 2019, 140
[33]   COST-EFFECTIVENESS ANALYSIS OF METFORMIN COMBINED WITH SAXAGLIPTIN VS. METFORMIN COMBINED WITH SULFONYLUREAS IN TYPE 2 DIABETES PATIENTS IN ARGENTINA [J].
Elgart, J. ;
Caporale, J. ;
Gagliardino, J. J. ;
Aiello, E. C. ;
Waschbusch, M. ;
Jotimliansky, L. .
VALUE IN HEALTH, 2010, 13 (03) :A61-A61
[34]   COST-EFFECTIVENESS OF SAXAGLIPTIN AND LINAGLIPTIN IN COMBINATION WITH METFORMIN FOR TYPE II DIABETES: A DECISION-TREE ANALYSIS MODEL [J].
Sawant, R., V ;
Sansgiry, S. S. .
VALUE IN HEALTH, 2014, 17 (03) :A250-A251
[35]   Screening for type 2 diabetes mellitus: A cost-effectiveness analysis [J].
Hoerger, TJ ;
Harris, R ;
Hicks, KA ;
Donahue, K ;
Sorensen, S ;
Engelgau, M .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (09) :689-699
[36]   THE COST-EFFECTIVENESS ANALYSIS OF VIDALGLIPTIN IN TYPE 2 DIABETES IN POLAND [J].
Walczak, J. ;
Nogas, G. ;
Gebus, E. ;
Pawlik, D. ;
Pacocha, K. .
VALUE IN HEALTH, 2009, 12 (07) :A406-A406
[37]   COST-EFFECTIVENESS OF DAPAGLIFLOZIN ALONE OR IN COMBINATION WITH SAXAGLIPTIN ADDED TO STANDARD OF CARE FOR THE MANAGEMENT OF DIABETIC KIDNEY DISEASE IN THE UNITED STATES [J].
Abegaz, T. ;
Fatimah, S. ;
Diaby, V ;
Ali, A. A. .
VALUE IN HEALTH, 2022, 25 (07) :S370-S371
[38]   COST-EFFECTIVENESS OF LIRAGLUTIDE FOR SUBJECTS WITH TYPE 2 DIABETES IN SPAIN [J].
Ramirz de Arellano, A. ;
Hunt, B. ;
Mezquita Raya, P. ;
Briones, T. ;
Perez, A. ;
Valentine, W. J. .
VALUE IN HEALTH, 2014, 17 (03) :A249-A250
[39]   COST-EFFECTIVENESS OF NEW ANTIDIABETICS IN TYPE 2 DIABETES: A REVIEW [J].
Baytar, S. ;
Malhan, S. .
VALUE IN HEALTH, 2010, 13 (07) :A292-A292
[40]   The cost-effectiveness of insulin glulisine in type 2 diabetes in Poland [J].
Walczak, J. ;
Dardzinski, W. ;
Kusy, M. ;
Lis, J. ;
Nogas, G. .
VALUE IN HEALTH, 2008, 11 (03) :A226-A226
12345